2658-6533Research Results in Biomedicine2658-653310.18413/2658-6533-2024-10-3-0-13502Genetics<strong><em>Mycobacterium tuberculosis</em> gene variants associated with drug resistance to fluoroquinolones (literature review)</strong><strong><em>Mycobacterium tuberculosis</em> gene variants associated with drug resistance to fluoroquinolones (literature review)</strong>GordeevaElizaveta I.GordeevaElizaveta I.mbtnniit20@gmail.comFilippovPavel N.FilippovPavel N.filippovPN@dcli.ruTursunovaNatalia V.TursunovaNatalia V.natalya-tursunova@mail.ruSalminAlexey V.SalminAlexey V.salmin.a@list.ru202410300

Background: The spread of M. tuberculosis drug resistance to fluoroquinolones poses a threat to their long-term clinical efficacy. Understanding the mechanisms of formation of drug resistance to fluoroquinolones, based on information on genes associated with drug resistance of M. tuberculosis, is important for optimizing TB chemotherapy regimens. The aim of the study: To study the available literature data on the most significant variants of M. tuberculosis genes associated with drug resistance to fluoroquinolones. Materials and methods: To achieve this goal, the task was to analyze the sources of domestic and foreign literature on this priority issue over the past 5 years. The databases of scientific electronic libraries PubMed, Elibriary were used. Results: Mycobacterial resistance to fluoroquinolones is associated with mutations in the gyrA and gyrB genes, encoding the GyrA and GyrB subunits of DNA gyrase, the main target of fluoroquinolones. In the fluoroquinolone-binding pocket of the &ldquo;DNA-gyrase + DNA&rdquo; catalytic center, the fluoroquinolone molecule is supported by the gyrA and gyrB regions, which determine resistance to fluoroquinolones (QRDR-A and QRDR-B). Modification of any of the constituent fragments of these regions affects the level of resistance to fluoroquinolones. Small quinolone molecules (nalidixic acid) have a high MIC against Mtb and other bacteria, while larger PC molecules (sparfloxacin, sitafloxacin, gatifloxacin, levofloxacin and moxifloxacin) are tightly adjacent to the fluoroquinolone-binding pocket and have a lower MIC. Modification of the DNA structure can change the spatial structure of the pocket itself, which leads to destabilization of the fluoroquinolone inside it. Thus, the presence of heteroresistance of the tuberculosis pathogen to fluoroquinolones indicates the active development of its resistance to this group of drugs in modern conditions. Conclusion: Analysis of modern studies shows the dependence of drug resistance of mycobacteria on fluoroquinolone compounds, while most often resistance to a decrease in the concentration of fluoroquinolones is associated with substitutions in the gyrB gene, as well as mutations in the gyrA gene. It has also been established that in addition to the main studied regions of the gyrA and gyrB genes associated with phenotypic drug resistance to fluoroquinols, there are regions that have not been sufficiently studied so far. These areas cannot be diagnosed in the clinical work of bacteriological laboratories of anti-tuberculosis institutions

Background: The spread of M. tuberculosis drug resistance to fluoroquinolones poses a threat to their long-term clinical efficacy. Understanding the mechanisms of formation of drug resistance to fluoroquinolones, based on information on genes associated with drug resistance of M. tuberculosis, is important for optimizing TB chemotherapy regimens. The aim of the study: To study the available literature data on the most significant variants of M. tuberculosis genes associated with drug resistance to fluoroquinolones. Materials and methods: To achieve this goal, the task was to analyze the sources of domestic and foreign literature on this priority issue over the past 5 years. The databases of scientific electronic libraries PubMed, Elibriary were used. Results: Mycobacterial resistance to fluoroquinolones is associated with mutations in the gyrA and gyrB genes, encoding the GyrA and GyrB subunits of DNA gyrase, the main target of fluoroquinolones. In the fluoroquinolone-binding pocket of the &ldquo;DNA-gyrase + DNA&rdquo; catalytic center, the fluoroquinolone molecule is supported by the gyrA and gyrB regions, which determine resistance to fluoroquinolones (QRDR-A and QRDR-B). Modification of any of the constituent fragments of these regions affects the level of resistance to fluoroquinolones. Small quinolone molecules (nalidixic acid) have a high MIC against Mtb and other bacteria, while larger PC molecules (sparfloxacin, sitafloxacin, gatifloxacin, levofloxacin and moxifloxacin) are tightly adjacent to the fluoroquinolone-binding pocket and have a lower MIC. Modification of the DNA structure can change the spatial structure of the pocket itself, which leads to destabilization of the fluoroquinolone inside it. Thus, the presence of heteroresistance of the tuberculosis pathogen to fluoroquinolones indicates the active development of its resistance to this group of drugs in modern conditions. Conclusion: Analysis of modern studies shows the dependence of drug resistance of mycobacteria on fluoroquinolone compounds, while most often resistance to a decrease in the concentration of fluoroquinolones is associated with substitutions in the gyrB gene, as well as mutations in the gyrA gene. It has also been established that in addition to the main studied regions of the gyrA and gyrB genes associated with phenotypic drug resistance to fluoroquinols, there are regions that have not been sufficiently studied so far. These areas cannot be diagnosed in the clinical work of bacteriological laboratories of anti-tuberculosis institutions

tuberculosisfluoroquinolonesdrug resistanceMycobacterium tuberculosistuberculosisfluoroquinolonesdrug resistanceMycobacterium tuberculosisСписок литературыAntropova GA, Okonenko TI. Pharmaceutical services: focus on fluorqinolones. Vestnik Novgorodskogo gosudarstvennogo universiteta. 2021;124(3):65-72. Russian. DOI: https://doi.org/10.34680/2076-8052.2021.3(124).65-72Panova AE, Vinokurov AS, Shemetova AA, et al. Molecular characteristics of Mycobacterium tuberculosis drug-resistant isolates from HIV- and HIV+ tuberculosis patients in Russia. BMC Microbiology. 2022;22(1):138. DOI: https://doi.org/10.1186/s12866-022-02553-7Vasilyeva IA, Testov VV, Sterlikov SA. Tuberculosis Situation in the Years of the COVID-19 Pandemic &ndash; 2020-2021. Tuberculosis and Lung Diseases. 2022;100(3):6-12. Russian. DOI: https://doi.org/10.21292/2075-1230-2022-100-3-6-12Zemlyanko OM, Rogoza TM, Zhouravleva GA. Mechanisms of bacterial multiresistance to antibiotics. Ecological genetics. 2018;16(3):4-17. Russian. DOI: https://doi.org/10.17816/ecogenl634-17Isaeva YuD, Krylova LYu, Makarova MV, et al. Detection of main characteristics of resistance of M. tuberculosis to fluoroquinolones and aminoglycosides/capreomycin. Tuberkulez i Sotsialno-Znachimye Zabolevaniya. Russian.Analytical reviews on tuberculosis [Internet] [cited 2023 Oct 6]. Russian. Available from: https://old.mednet.ru/images/stories/files/CMT/tb_resursy_2016-2017.pdfMatchanova FS. Relevance of the problem of resistance to antimicrobialpreparations in the world. Vestnik Kaz NMU. 2018;2:365-368. Russian.Efimenko TA, Terekhova LP, Efremenkova OV. Current State the Problem of Antibiotic Resistance of Pathogens. Antibiotics and Chemotherapy. 2019;64(5-6):64-68. Russian. DOI: https://doi.org/10.24411/0235-2990-2019-100033World Health Organization et al. Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance [Internet]; 2021 [cited 2023 Oct 6]. Available from: https://www.who.int/publications/i/item/9789240028173Singh PK, Singh U, Jain A. Emergence of Specific gyrA Mutations Associated High-Level Fluoroquinolone-Resistant Mycobacterium tuberculosis among Multidrug-Resistant Tuberculosis Cases in North India. Microbial Drug Resistance. 2021;27(5):647-651. DOI: &nbsp;https://doi.org/10.1089/mdr.2020.0240Sirgel FA, Warren RM, Streicher EM, et al. GyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. Journal of Antimicrobial Chemotherapy. 2012;67(5):1088-1093. DOI: https://doi.org/10.1093/jac/dks033Hasan Z, Razzak SA, Kanji A, et al. Whole-genome sequencing reveals genotypic resistance in phenotypically susceptible Mycobacterium tuberculosis clinical isolates. International Journal of Mycobacteriology. 2023;12(2):179-183. DOI: https://doi.org/10.4103/ijmy.ijmy_101_23Pushilina AD, Komenkova TS, Zaitseva EA. Microorganisms antibiotic resistance mechanisms - present view. Medical &amp; Pharmaceutical Journal &laquo;Pulse&raquo;. 2019;21(10):125-130. Russian. DOI: http://dx.doi.org/10.26787/nydha-2686-6838-2019-21-10-125-130Grebnev DYu, Osipenko AV, Ryabov RV, et al. Macroautophagy and its Role in the Pathogenesis of Tuberculosis. Journal of Ural Medical Academic Science. 2021;18(2):95-109. Russian. DOI: https://doi.org/10.22138/2500-0918-2021-18-2-95-109Felker IG, Gordeeva EI, Stavitskaya NV, et al. Prospects and Obstacles for Clinical Use of the Inhibitors of Mycobacterium tuberculosis Efflux Pumps. Biologicheskie membrany. 2021;38(5):317-339. Russian. DOI: https://doi.org/10.31857/S0233475521050054 &nbsp;Nosova EYu, Khаkhаlinа АА, Isakovа АI, et al. Simultaneius detection of genetic determinants of extensively drug resistance and genotyping of M. tuberculosis by hybridization on biochips. Tuberculosis and socially significant diseases. 2016;2:24-32. Russian.Maruri F, Guo Y, Blackman A, et al. Resistance-Conferring Mutations on Whole-Genome Sequencing of Fluoroquinolone-resistant and -Susceptible Mycobacterium tuberculosis Isolates: A Proposed Threshold for Identifying Resistance. Clinical Infectious Diseases. 2021;72(11):1910-1918. DOI: https://doi.org/10.1093/cid/ciaa496Khakhalina AA, Krasnova EM, Belilovsky IV, et al. Population structure of multidrug-resistant Mycobacterium tuberculosis in Moscow. Tuberculosis and socially significant diseases. 2019;2:29-39. Russian.Faksri K, Kaewprasert O, Ong RTH, et al. Comparisons of whole-genome sequencing and phenotypic drug susceptibility testing for Mycobacterium tuberculosis causing MDR-TB and XDR-TB in Thailand. International Journal of Antimicrobial Agents. 2019;54(2):109-116. DOI: https://doi.org/10.1016/j.ijantimicag.2019.04.004Sutormin DA, Galivondzhyan AKh, Polkhovskiy AV, et al. Diversity and functions of type II topoisomerases. Acta Naturae. 2021;13(1):59-70. Russian. DOI: https://doi.org/10.32607/actanaturae.11058Byl JAW, Mueller R, Bax B, et al. A Series of Spiropyrimidinetriones that Enhances DNA Cleavage Mediated by Mycobacterium tuberculosis Gyrase. ACS Infectious Diseases. 2023;9(3):706-715. DOI: https://doi.org/10.1021/acsinfecdis.3c00012Egorov AM, Ulyashova MM, Rubtsova MYu. Bacterial Enzymes and Antibiotic Resistance. Acta Naturae. 2018;10(4):33-48. Russian.Avalos E, Catanzaro D, Catanzaro A, et al. Frequency and Geographic Distribution of gyrA and gyrB Mutations Associated with Fluoroquinolone Resistance in Clinical Mycobacterium Tuberculosis Isolates: A Systematic Review. PLoS ONE. 2015;10(3):e0120470. DOI: https://doi.org/10.1371/journal.pone.0120470Bi J, Guo Q, Fu X,&nbsp;et al. Characterizing the gene mutations associated with resistance to gatifloxacin in Mycobacterium tuberculosis through whole-genome sequencing. International Journal of Infectious Diseases. 2021;112:189-194. DOI: https://doi.org/10.1016/j.ijid.2021.09.028Tang J, Brynildsen MP. Genome-wide mapping of fluoroquinolone-stabilized DNA gyrase cleavage sites displays drug specific effects that correlate with bacterial persistence. Nucleic Acids Research. 2013;51(3):1208-1228. DOI: https://doi.org/10.1093/nar/gkac1223Singh PK, Singh U, Jain A. Emergence of Specific gyrA Mutations Associated High-Level Fluoroquinolone-Resistant Mycobacterium tuberculosis among Multidrug-Resistant Tuberculosis Cases in North India. Microbial Drug Resistance. 2021;27(5):647-651. DOI: https://doi.org/10.1089/mdr.2020.0240Brankin AE, Flower PW. Inclusion of minor alleles improves catalogue-based prediction of fluoroquinolone resistance in Mycobacterium tuberculosis. JAC-Antimicrobial Resistance. 2023;5(2):dlad039. DOI: https://doi.org/10.1093/jacamr/dlad039Wang Z, Sun R, Mu C, et al. Characterization of Fluoroquinolone-Resistant and Multidrug-Resistant Mycobacterium tuberculosis Isolates Using Whole-Genome Sequencing in Tianjin, China. Infection and Drug Resistance. 2022;15:1793-1803. DOI: https://doi.org/10.2147/IDR.S361635Singh A, Zhao X, Drlica K. Fluoroquinolone heteroresistance, antimicrobial tolerance, and lethality enhancement. Frontiers in Cellular and Infection Microbiology. 2022;12:938032. DOI: https://doi.org/10.3389/fcimb.2022.938032Malik S, Willby M, Sikes D, et al. New Insights into Fluoroquinolone Resistance in Mycobacterium tuberculosis: Functional Genetic Analysis of gyrA and gyrB Mutations. PLoS ONE. 2012;7(6):e39754. DOI: https://doi.org/10.1371/journal.pone.0039754Matrat S, Aubry A, Mayer C, et al. Mutagenesis in the &alpha;3&alpha;4 GyrA helix and in the toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. Antimicrobial Agents and Chemotherapy. 2008;52(8):2909-2914. DOI: https://doi.org/10.1128/AAC.01380-07Mujuni D, Kasemire DL, Ibanda I, et al. Molecular characterisation of second-line drug resistance among drug resistant tuberculosis patients tested in Uganda: a two and a half-year&rsquo;s review. BMC Infectious Diseases. 2022;22:363. DOI: https://doi.org/10.1186/s12879-022-07339-wSayadi M, Zare H, Jamedar SA, et al. Genotypic and phenotypic characterization of Mycobacterium tuberculosis resistance against fluoroquinolones in the northeast of Iran. BMC Infectious Diseases. 2020;20:390. DOI: https://doi.org/10.1186/s12879-020-05112-5Shur KV, Bekker OB, Zaichikova MV, et al. Genetic Aspects of Mycobacterium tuberculosis Drug Resistance and Virulence. Russian Journal of Genetics. 2018;54(12):1363-1375. Russian. DOI: https://doi.org/10.1134/S0016675818120147Chien JY, Chiu WY, Chien ST, et al. Mutations in gyrA and gyrB among Fluoroquinolone- and Multidrug-Resistant Mycobacterium tuberculosis Isolates. &nbsp;Antimicrobial Agents and Chemotherapy.&nbsp;2016;60(4):2090-2096. DOI: https://doi.org/10.1128/AAC.01049-15Lau RWT, Ho PL, Kao RYT, et al. Molecular characterization of fluoroquinolone resistance in Mycobacterium tuberculosis: functional analysis of gyrA mutation at position 74. Antimicrobial Agents and Chemotherapy. 2011;55(2):608-614. DOI: https://doi.org/10.1128/AAC.00920-10Zhang X, Chen X, Wang B, et al. Molecular characteristic of both levofloxacin and moxifloxacin resistance in Mycobacterium tuberculosis from individuals diagnosed with preextensive drug-resistant tuberculosis. Microbial Drug Resistance. 2022;28(3):280-287. DOI: https://doi.org/10.1089/mdr.2021.0212Yadav R, Saini A, Agarwal P, et al. A Rare D94F Change in gyrA Gene of Multidrug-Resistant Mycobacterium tuberculosis Possibly Contributing to an Unfavorable Treatment Outcome. Antimicrobial Agents and Chemotherapy. 2019;63(11):e01312-19. DOI: https://doi.org/10.1128/AAC.01312-19Mahmood N, Abbas SN, Faraz N, et al. Mutation analysis of gyrB at amino acid: G481A&amp; D505A in multi drug resistance (MDR) tuberculosis patients. Journal of Infection and Public Health. 2019;12(4):496-501.&nbsp;DOI: https://doi.org/10.1016/j.jiph.2019.01.056Willby M, Chopra P, Lemmer D, et al. Molecular evaluation of fluoroquinolone resistance in serial Mycobacterium tuberculosis isolates from individuals diagnosed with multidrug-resistant tuberculosis. Antimicrobial Agents and Chemotherapy. 2020;65(51):860-865. DOI: https://doi.org/10.1128/AAC.01663-20Qiao M, Ren W, Guo H, et al. Comparative in vitro susceptibility of a novel fluoroquinolone antibiotic candidate WFQ-228, levofloxacin, and moxifloxacin against Mycobacterium tuberculosis. International Journal of Infectious Diseases. 2021;106:295-299. DOI: https://doi.org/10.1016/j.ijid.2021.04.036Kamsri B, Pakamwong B, Thongdee P, et al. Bioisosteric Design Identifies Inhibitors of Mycobacterium tuberculosis DNA Gyrase ATPase Activity. Journal of Chemical Information and Modeling. 2023;63(9):2707-2718. DOI: https://doi.org/10.1021/acs.jcim.2c01376